Related Experiment Video

Updated: Aug 5, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Voriconazole (Pfizer ltd)

P E Verweij1, B E de Pauw, J F Meis

  • 1Departments of Medical Microbiology and Hematology, University Hospital Nijmegen, The Netherlands. p.verweij@mmb.azn.nl

Idrugs : the Investigational Drugs Journal
|August 27, 2005
PubMed

Insights

Voriconazole shows promise as a treatment for invasive fungal infections, including aspergillosis and candidiasis, particularly in immunocompromised patients. Clinical trials indicate significant efficacy, even when other antifungals have failed.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Emerging fungal infections pose a significant threat to immunocompromised individuals.
  • Voriconazole is a novel antifungal agent developed by Pfizer.
  • Existing treatments like amphotericin have limitations in efficacy and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of voriconazole in treating various fungal infections.
  • To compare voriconazole's activity against other antifungal agents.
  • To assess voriconazole's potential in treating infections caused by resistant fungal strains.

Main Methods:

  • Phase III clinical trials involving immunocompromised patients with aspergillosis and candidiasis.
  • In vitro studies comparing voriconazole's activity against comparator agents.
  • Analysis of clinical efficacy data from patient trials.

Main Results:

  • Voriconazole demonstrated clinical efficacy of at least 69% in trials.
  • The compound was effective in patients who did not respond to amphotericin B.
  • In vitro studies showed voriconazole to be highly active against certain Scedosporium species.

Conclusions:

  • Voriconazole is effective and well-tolerated for treating invasive aspergillosis and candidiasis in various patient populations.
  • The drug exhibits an extended spectrum of activity compared to existing treatments.
  • Voriconazole holds potential for treating serious fungal infections affecting the eye and brain.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...